In a move that marks a significant advancement in the treatment of sickle cell disease (SCD), the FDA has announced approval for Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CasgevyIn and bluebird bio’s Lyfgenia. This approval for cell-based gene therapies, tailored for individuals aged 12 and older, provides assistance to approximately 100,000 people dealing with this inherited blood disorder in the United States.
Associated with the FDA’s Center for Biologics Evaluation and Research in the Office of Therapeutic Products, Director Dr. Nicole Verdun, shared optimism about the potential impact of these therapies on individuals whose lives have been severely affected by SCD. She highlighted the importance of gene therapy in delivering targeted and effective treatments, particularly for rare diseases where therapeutic options are scarce.
Casgevy, a collaborative development by Vertex Pharmaceuticals and CRISPR Therapeutics, distinguishes itself as the inaugural FDA-approved genome editing technology for sickle cell disease (SCD). Vertex’s CEO, Dr. Reshma Kewalramani, emphasized Casgevy’s distinction as the initial CRISPR-based gene-editing therapy in the U.S., holding promise for a potential one-time transformative therapy for eligible patients.
The FDA’s endorsement of Casgevy was based on compelling data obtained from both the Phase 1/2/3 CLIMB-121 clinical trial and the Phase 3 long-term follow-up CLIMB-131 trial. Notably, during a 24-month follow-up period, 29 out of 31 evaluated sickle cell disease (SCD) patients achieved freedom from vaso-occlusive crises (VOCs) for a minimum of 12 consecutive months.
Lyfgenia, crafted by bluebird bio, involves autologous CD34+ hematopoietic stem cells modified with the BB305 lentiviral vector. It was the results from the Phase 3 HGB-210 clinical trial and the ongoing Phase 1/2 HGB-206 clinical trial that earned Lyfgenia the green light from the FDA. The results of the trial revealed that over 80% of patients between six and 18 months post-infusion experienced complete resolution of vaso-occlusive events.
Both Casgevy and Lyfgenia are administered as a single dose and one-time treatment. They both also make use of patients’ blood stem cells in the treatment. Despite this achievement, considerations for long-term safety and efficacy are paramount. Lyfgenia, in particular, carries a black box warning about the risk of hematologic malignancy, necessitating lifelong monitoring for patients undergoing this therapy.
A representative from the FDA Center for Biologics Evaluation and Research emphasized that these approvals signify a noteworthy medical advance, showcasing innovative cell-based gene therapies effectively addressing severe health conditions.
The significance of these approvals extends beyond scientific progress. Given the disproportionate impact of SCD on the Black population, these therapies are crucial for addressing health disparities. The high cost associated with these therapies raises questions about accessibility and coverage, prompting considerations about equitable distribution.
In pursuing a cure, the FDA’s approval of Casgevy, combined with Lyfgenia, represents a transformative step forward. While hailed as a significant breakthrough, experts acknowledge that challenges persist in simplifying administration, ensuring safety, and defining the elusive term “cure” in the context of SCD.
